Resmed (RMD) Common Equity (2010 - 2026)

Resmed's Common Equity history runs 17 years deep, the most recent figure standing at $6.5 billion for Q1 2026.

• Quarterly Common Equity rose 17.05% year-over-year to $6.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 billion (up 17.05% YoY) and the FY2025 annual result came in at $761000.0, down 99.98% from the prior year.
• Common Equity was $6.5 billion for Q1 2026 at Resmed, up from $6.3 billion in the prior quarter.
• Across five years, Common Equity topped out at $6.5 billion in Q1 2026 and bottomed at $761000.0 in Q2 2025.
• A 5-year average of $4.4 billion and a median of $4.5 billion in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity advanced 23.81% — and 2025, when it plunged 99.98%.
• Resmed's Common Equity stood at $3.7 billion in 2022, then advanced by 19.9% to $4.5 billion in 2023, then advanced by 17.21% to $5.3 billion in 2024, then climbed by 20.33% to $6.3 billion in 2025, then rose by 2.71% to $6.5 billion in 2026.
• Business Quant data shows RMD's Common Equity at $6.5 billion in Q1 2026, $6.3 billion in Q4 2025, and $6.1 billion in Q3 2025.